Agilent Technologies, Inc. $A Shares Sold by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

Key Points

• MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. reduced its investment in Agilent Technologies by 4% during the first quarter, leaving it with a stake valued at approximately $9.46 million.
• Agilent Technologies reported a 10.1% year-over-year revenue increase in its latest quarterly earnings, achieving a net margin of 17.97% and meeting expectations with an earnings per share (EPS) of $1.37.
• Several institutional investors have recently modified their holdings in Agilent, with institutional ownership now at 87.41% of the company's stock.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lowered its stake in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 4.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 80,889 shares of the medical research company's stock after selling 3,331 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Agilent Technologies were worth $9,462,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in A. Whipplewood Advisors LLC boosted its position in Agilent Technologies by 286.2% during the 1st quarter. Whipplewood Advisors LLC now owns 251 shares of the medical research company's stock valued at $29,000 after purchasing an additional 186 shares during the period. Sunbelt Securities Inc. boosted its position in Agilent Technologies by 640.0% during the 4th quarter. Sunbelt Securities Inc. now owns 222 shares of the medical research company's stock valued at $30,000 after purchasing an additional 192 shares during the period. Stone House Investment Management LLC acquired a new position in Agilent Technologies during the 1st quarter valued at approximately $30,000. Opal Wealth Advisors LLC acquired a new position in Agilent Technologies during the 1st quarter valued at approximately $31,000. Finally, Wood Tarver Financial Group LLC acquired a new position in Agilent Technologies during the 4th quarter valued at approximately $34,000.

Insider Activity at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the business's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total value of $177,099.52. Following the sale, the chief executive officer owned 37,448 shares of the company's stock, valued at approximately $4,397,893.12. The trade was a 3.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Agilent Technologies Price Performance

Shares of A traded up $1.90 during midday trading on Monday, reaching $125.14. The stock had a trading volume of 381,957 shares, compared to its average volume of 1,941,289. Agilent Technologies, Inc. has a 52 week low of $96.43 and a 52 week high of $153.84. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71. The firm's 50 day moving average price is $119.76 and its 200-day moving average price is $115.79. The company has a market capitalization of $35.48 billion, a P/E ratio of 29.40, a P/E/G ratio of 3.83 and a beta of 1.24.

Agilent Technologies (NYSE:A - Get Free Report) last posted its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, hitting analysts' consensus estimates of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.67 billion. During the same quarter in the previous year, the business earned $1.32 EPS. The company's quarterly revenue was up 10.1% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, analysts forecast that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. TD Cowen boosted their price objective on Agilent Technologies to $150.00 and gave the company a "buy" rating in a research report on Thursday, May 29th. Robert W. Baird increased their price target on Agilent Technologies from $141.00 to $142.00 and gave the stock an "outperform" rating in a research note on Thursday, August 28th. UBS Group lowered their price target on Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating on the stock in a report on Thursday, May 29th. Evercore ISI cut their price objective on shares of Agilent Technologies from $130.00 to $128.00 and set an "in-line" rating on the stock in a research note on Thursday, August 28th. Finally, Leerink Partners lifted their price objective on shares of Agilent Technologies to $135.00 and gave the company a "buy" rating in a research note on Friday, May 30th. Six analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $140.08.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.